BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, March 25, 2026
Breaking News: Trump administration impacts continue to roil the life sciences sector
See today's BioWorld Science
Home
» Merck Sharp & Dohme prepares new KRAS G12D degrader PROTACs
To read the full story,
subscribe
or
sign in
.
Cancer
Merck Sharp & Dohme prepares new KRAS G12D degrader PROTACs
Feb. 13, 2025
Merck Sharp & Dohme LLC patents report the development of proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase (Von Hippel-Lindau disease tumor suppressor [VHL] ligands) coupled to GTPase KRAS (G12D mutant)-targeting moiety through a linker.
BioWorld Science
Cancer
Patents
